|Description||CI 1020 has been found to be a novel endothelin-A receptor antagonist and could be used as an antihypertensive agent.|
|Purity||≥98% by HPLC|
|Synonyms||CI 1020; CI1020; CI-1020; 3-(1,3-Benzodioxol-5-yl)-5-hydroxy-5-(4-methoxyphenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]-2(5H)-furanone|
CI 1020 has been found to be a novel endothelin-A receptor antagonist and could be used as an antihypertensive agent.
Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.
Avosentan, also known as SPP301, R-639, and RO 67-0565, is a potent and selective endothelin receptor(ETA receptor) antagonist.
Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.
Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the treatment of pulmonary arterial hyperten...
Endothelin 3 (human, rat)
Endothelin 3 is a ligand of the endothelin (ET) receptors and a potent vasoconstrictor. Endothelin 3 increases blood pressure in spontaneously hypertensive and ...
BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.